Beck Bode LLC Buys New Stake in Guardant Health, Inc. (NASDAQ:GH)

Beck Bode LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 142,745 shares of the company’s stock, valued at approximately $3,861,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. CWM LLC lifted its position in shares of Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after purchasing an additional 569 shares in the last quarter. BluePath Capital Management LLC acquired a new position in shares of Guardant Health during the third quarter worth approximately $35,000. Headlands Technologies LLC lifted its position in shares of Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after purchasing an additional 1,844 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after purchasing an additional 614 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Guardant Health by 26.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock worth $102,000 after purchasing an additional 713 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

GH stock traded down $0.19 during trading hours on Tuesday, reaching $18.00. The stock had a trading volume of 1,168,510 shares, compared to its average volume of 1,865,512. The stock has a market capitalization of $2.19 billion, a PE ratio of -4.21 and a beta of 0.87. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24. The stock has a 50-day simple moving average of $18.65 and a 200 day simple moving average of $22.75. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $41.06.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The company had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. Analysts predict that Guardant Health, Inc. will post -3.49 EPS for the current fiscal year.

Insider Transactions at Guardant Health

In related news, insider Kumud Kalia bought 2,187 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was bought at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the purchase, the insider now owns 12,722 shares in the company, valued at approximately $226,706.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

GH has been the topic of several analyst reports. Piper Sandler cut their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. JPMorgan Chase & Co. lowered their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Canaccord Genuity Group lowered their target price on shares of Guardant Health from $45.00 to $30.00 and set a “buy” rating for the company in a research note on Monday. Craig Hallum initiated coverage on shares of Guardant Health in a research note on Wednesday, April 24th. They issued a “buy” rating and a $28.00 target price for the company. Finally, Guggenheim reissued a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.91.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.